European Primary Care Cardiovascular Society
AHA 2019 Considering the epidemic of e-cigarette use, particularly among young people, AHA announced substantial investment in research and activities to raise awareness about the risks of vaping.
AHA 2019 Daily colchicine lowered ischemic events, mostly urgent revascularization, in patients with an MI less than 30 days ago, in the COLCOT trial. Colchicine was well-tolerated.
A study using data of millions of patients showed that there are no differences in effectiveness between drug classes when initiating monotherapy for hypertension, with the exception of lower risk of MI, HHF and stroke with thiazide or thiazide-like diuretics when compared to ACEi.
EPCCS 2019 Monika Hollander asks Peter van der Meer how comorbidities like renal dysfunction and cancer treatment affects management of patients with HF: what is known about treatment in patients with these comorbidities?
This review comprehensively summarizes both preclinical and clinical data on the CV effects of e-cigarette use. CV effects of e-cigarette constituents as well as of e-cigarette exposure are reviewed. With poll
A brief impression of how EPCCS activities and plans can be useful for primary care physicians in Poland.
A brief impression of how EPCCS activities and plans can be useful for primary care physicians in Ukraine.
A brief impression of how EPCCS activities and plans can be useful for primary care physicians in Turkey.
A study of real-world data of 4 large European primary care databases demonstrates that NAFLD is not associated with increased risk of AMI and stroke, after correction for traditional risk factors.
A randomized clinical trial of hypertensive patients demonstrates that ingestion of hypertension medication at bedtime reduces asleep ABP and CVD event risk compared to ingestion upon awakening.
In a Danish cohort study of nonvalvular AF patients, DOAC use was associated with a lower risk of osteoporotic fractures compared to VKA treatment.
ESC 2019 Two experts took opposite sides of the statement ‘fish oil: it’s all about triglycerides’ and presented evidence to back up their statements, including data of the REDUCE-IT trial. With poll
